Recombinant Human Papillomavirus 15-valent Vaccine (Escherichia. Coli) (HPV 15)
Classification:
Products in the Pipeline
- Product Description
- Immunogenicity
- Security
- Mad Dog Bite Cases
-
Manufacturing Process
At present, it is the HPV vaccine with the highest valence in China, achieving full coverage of high-risk HPV viruses announced by WHO, and demonstrating a better preventive effect against HPV introduced infection. Through the innovative molecular design of antigen, HPV 15 has advantages such as a stable manufacturing process, a short manufacturing cycle, high purity, strong efficacy and good safety.
Current Progress
The project is under Phase I clinical trial.
Next Page
Next Page
Other Products
Inactivated Japanese Encephalitis Vaccine for Human Use (Vero cell) (IJEV)
SPEEDA-Rabies Vaccine for Human Use (Vero cell) (CPRV)
Rabies Vaccine (Human Diploid Cell) for Human Use, Freeze-dried (HDCV)
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (QIV)
13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV 13)
Recombinant Human Papillomavirus 15-valent Vaccine (Escherichia. Coli) (HPV 15)
Follow us
Telephone
Marketing Center
International Trade
Medical Consultation
Address
No.1, XinFang Street, Hunnan New District, Shenyang City
123456789
12456789